$RFL

Rafael Holdings reported FY 2026 revenue of $874K, with healthcare revenue at $519K and real estate rental revenue at $355K. Net loss narrowed to $29.6M from $30.5M, but operating loss widened to $33.4M due to higher healthcare R&D spending. The company completed a Phase 3 trial for Trappsol Cyclo and submitted an NDA, pending FDA review.

Rafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update NEWARK, NJ – October 29, 2026 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fi

Rafael Holdings (RFL) reported Q4 GAAP EPS of -$0.18 and revenue of $0.24M, down 31.4% year-over-year. The company also discussed topline results of a Phase III study for Trappsol Cyclo in Niemann-Pick Disease Type C.

Rafael Holdings (NYSE: RFL) subsidiary Cyclo Therapeutics submitted an NDA for remibetadex, a treatment for Niemann-Pick Disease Type C. The Phase 3 study did not meet its primary endpoint but showed a 64% slowing of disease progression. The FDA will review the application within 60 days. Remibetadex has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations.

Rafael Holdings Inc Class B (RFL) shares dropped 25% premarket after its Phase 3 trial for Trappsol Cyclo in Niemann-Pick Disease Type C missed the primary endpoint. The drug showed a 64% slowing of disease progression but lacked statistical significance (p=0.19). A subgroup analysis found significant results (p=0.046). The company plans to submit a New Drug Application by Q4 2026.

Rafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC ™ Study of Trappsol ® Cyclo ™ in Niemann-Pick Disease Type C (NPC) Trappsol ® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect v

Rafael Holdings (RFL) reported Phase 3 results for Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC). While the primary endpoint did not achieve statistical significance, a prespecified analysis in patients on background therapy showed a significant benefit. The drug was well-tolerated. The company plans to submit an NDA in Q4 2026.

Rafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029432001ex99-1.htm PRESS RELEASE, DATED JUNE 11, 2026, REPORTING THE RESULTS OF OPERATIONS FOR THE FISCAL QUARTER ENDED APRIL 30, 2026 Exhibit 99.1 Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results NEWARK, NJ – June 11, 2026 (GLOBE NEWSWIRE) - Rafae

Rafael Holdings (NYSE: RFL) reported a wider net loss of $16.2 million for the six months ended January 31, 2026, compared to $13.6 million in the prior year, primarily due to a significant increase in research and development expenses, which rose to $12.0 million from $2.3 million. The company's revenue increased to $451 thousand, driven by rental income and new product sales. With a cash balance of $37.8 million, Rafael Holdings anticipates having sufficient liquidity for at least the next 12 months as it continues to focus on advancing its lead drug candidate, Trappsol® Cyclo™, through a pivotal Phase 3 clinical trial.

Rafael Holdings, Inc. (NYSE:RFL) held its annual meeting where shareholders elected directors, ratified CohnReznick LLP as their accounting firm, and approved an amendment to the company's 2021 Equity Incentive Plan. This amendment increases the shares of Class B common stock available for grant by 1,000,000. Additionally, the company recently issued warrants as part of its merger with Cyclo Therapeutics, which are now listed on NYSE American.